Insulet Corporation $PODD Shares Sold by Ayrshire Capital Management LLC

Ayrshire Capital Management LLC decreased its position in Insulet Corporation (NASDAQ:PODD) by 19.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 18,942 shares of the medical instruments supplier’s stock after selling 4,619 shares during the quarter. Insulet accounts for about 2.7% of Ayrshire Capital Management LLC’s investment portfolio, making the stock its 21st largest holding. Ayrshire Capital Management LLC’s holdings in Insulet were worth $5,848,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the company. Kozak & Associates Inc. acquired a new stake in Insulet during the 2nd quarter valued at $32,000. Golden State Wealth Management LLC boosted its position in Insulet by 202.9% in the 2nd quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier’s stock valued at $32,000 after buying an additional 69 shares during the last quarter. Trust Co. of Toledo NA OH acquired a new stake in shares of Insulet during the second quarter valued at about $35,000. Osterweis Capital Management Inc. acquired a new stake in shares of Insulet during the second quarter valued at about $51,000. Finally, NewEdge Advisors LLC increased its position in shares of Insulet by 44.8% during the first quarter. NewEdge Advisors LLC now owns 207 shares of the medical instruments supplier’s stock worth $54,000 after acquiring an additional 64 shares during the last quarter.

Analyst Ratings Changes

PODD has been the subject of a number of recent analyst reports. Canaccord Genuity Group raised their price objective on Insulet from $432.00 to $450.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. JPMorgan Chase & Co. increased their target price on Insulet from $340.00 to $415.00 and gave the company an “overweight” rating in a research note on Friday, September 12th. Evercore ISI started coverage on shares of Insulet in a research note on Tuesday, December 16th. They issued an “outperform” rating and a $370.00 price target for the company. Cowen reaffirmed a “buy” rating on shares of Insulet in a report on Thursday, December 4th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Insulet in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $379.00.

Insulet Stock Down 0.1%

PODD stock opened at $287.03 on Wednesday. The firm has a market cap of $20.19 billion, a price-to-earnings ratio of 83.20, a PEG ratio of 2.02 and a beta of 1.37. Insulet Corporation has a 1-year low of $230.05 and a 1-year high of $354.88. The firm has a fifty day moving average price of $312.04 and a two-hundred day moving average price of $312.77. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.87 and a quick ratio of 2.18.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 EPS for the quarter, beating the consensus estimate of $1.13 by $0.11. The business had revenue of $521.70 million during the quarter, compared to analyst estimates of $678.70 million. Insulet had a net margin of 9.76% and a return on equity of 24.36%. The company’s quarterly revenue was up 29.9% on a year-over-year basis. During the same period in the previous year, the business posted $1.08 EPS. Research analysts predict that Insulet Corporation will post 3.92 EPS for the current year.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.